A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor

Journal of Experimental Medicine

Volumn 208, Issue 5, 2011, Pages 973-986

  Chabot, Sophie ^a,b,c,d,g   Jabrane Ferrat, Nabila ^a,b,c,d   Bigot, Karine ^e,f   Tabiasco, Julie ^a,b,c,d   Provost, Alexandra ^e,f   Golzio, Muriel ^d,g   Noman, Muhammad Zaeem ^h   Giustiniani, Jérôme ^e,i,j   Bellard, Elisabeth ^d,g   Brayer, Stéphanie ^a,b,c   Aguerre Girr, Maryse ^a,b,c,d   Meggetto, Fabienne ^k   Giuriato, Sylvie ^k   Malecaze, François ^l   Galiacy, Stéphane ^l   Jaïs, Jean Philippe ^f   Chose, Olivier ^m   Kadouche, Jean ^m   Chouaib, Salem ^h   Teissié, Justin ^d,g   Abitbo, Marc ^e,f   Bensussan, Armand ^e,i   Le Bouteiller, Philippe ^a,b,c,d   more..

^a INSERM   (France)

^b CNRS   (France)

^c France   (France)

^d UNIVERSITÉ DE TOULOUSE   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j INSTITUT JEAN GODINOT   (France)

^k CANCER RESEARCH CENTER OF TOULOUSE   (France)

^l TOULOUSE UNIVERSITY HOSPITAL   (France)

^m MAT Biopharma   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD160 RECEPTOR; CL1 R2 MONOCLONAL ANTIBODY; CYCLOPHOSPHAMIDE; FIBROBLAST GROWTH FACTOR 2; IMMUNOGLOBULIN G1; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL; CANCER COMBINATION CHEMOTHERAPY; COLON CARCINOMA; CONTROLLED STUDY; CORNEA; DOPPLER ECHOGRAPHY; ENDOTHELIUM CELL; FLUORESCENCE MICROSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRAVITAL FLUORESCENCE MICROSCOPY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; RETINOPATHY; TUMOR VASCULARIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; CORNEAL NEOVASCULARIZATION; CYCLOPHOSPHAMIDE; FEMALE; FIBROBLAST GROWTH FACTOR 2; GPI-LINKED PROTEINS; HUMANS; MALE; MELANOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; RABBITS; RECEPTORS, IMMUNOLOGIC; RETINAL DISEASES;

EID: 79956157422     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20100810     Document Type: Article

References (63)

1. Ambati, B.K., M. Nozaki, N. Singh, A. Takeda, P.D. Jani, T. Suthar, R.J. Albuquerque, E. Richter, E. Sakurai, M.T. Newcomb, et al. 2006. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 443:993-997.
2. Anumanthan, A., A. Bensussan, L. Boumsell, A.D. Christ, R.S. Blumberg, S.D. Voss, A.T. Patel, M.J. Robertson, L.M. Nadler, and G.J. Freeman. 1998. Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes. J. Immunol. 161:2780-2790.
3. Asselin-Paturel, C., N. Lassau, J.M. Guinebretière, J. Zhang, F. Gay, F. Bex, S. Hallez, J. Leclere, P. Peronneau, F. Mami-Chouaib, and S. Chouaib. 1999. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography. Gene Ther. 6:606-615.
4. Barakonyi, A., M. Rabot, A. Marie-Cardine, M. Aguerre-Girr, B. Polgar, V. Schiavon, A. Bensussan, and P. Le Bouteiller. 2004. Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset. J. Immunol. 173:5349-5354.
5. Bensussan, A. 2000. BY55 (CD160). Protein Rev. Web. 1:72-73.
6. Bergers, G., and D. Hanahan. 2008. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer. 8:592-603.
7. Bock, F., J. Onderka, T. Dietrich, B. Bachmann, F.E. Kruse, M. Paschke, G. Zahn, and C. Cursiefen. 2007. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest. Ophthalmol. Vis. Sci. 48:2545-2552.
8. Buckanovich, R.J., A. Facciabene, S. Kim, F. Benencia, D. Sasaroli, K. Balint, D. Katsaros, A. O'Brien-Jenkins, P.A. Gimotty, and G. Coukos. 2008. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med. 14:28-36.
9. Cao, Y. 2009. Tumor angiogenesis and molecular targets for therapy. Front. Biosci. 14:3962-3973.
10. Cao, Y., and R. Langer. 2010. Optimizing the delivery of cancer drugs that block angiogenesis. Sci. Transl. Med. 2:ps3.
11. Carmeliet, P. 2005. Angiogenesis in life, disease and medicine. Nature. 438:932-936.
12. Chen, H.X., and J.N. Cleck. 2009. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 6:465-477.
13. Cursiefen, C. 2007. Immune privilege and angiogenic privilege of the cornea. Chem. Immunol. Allergy. 92:50-57.
14. Dastjerdi, M.H., K.M. Al-Arfaj, N. Nallasamy, P. Hamrah, U.V. Jurkunas, R. Pineda II, D. Pavan-Langston, and R. Dana. 2009. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch. Ophthalmol. 127:381-389.
15. Dorrell, M.I., E. Aguilar, L. Scheppke, F.H. Barnett, and M. Friedlander. 2007. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc. Natl. Acad. Sci. USA. 104:967-972.
16. Duch, S., O. Buchacra, E. Milla, D. Andreu, and J. Tellez. 2009. Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients. J. Glaucoma. 18:140-143.
17. Dufresne-Martin, G., J.F. Lemay, P. Lavigne, and K. Klarskov. 2005. Peptide mass fingerprinting by matrix-assisted laser desorption ionization mass spectrometry of proteins detected by immunostaining on nitrocellulose. Proteomics. 5:55-66.
18. Economopoulou, M., K. Bdeir, D.B. Cines, F. Fogt, Y. Bdeir, J. Lubkowski, W. Lu, K.T. Preissner, H.P. Hammes, and T. Chavakis. 2005. Inhibition of pathologic retinal neovascularization by alpha-defensins. Blood. 106:3831- 3838.
19. Elie, N., A. Kaliski, P. Péronneau, P. Opolon, A. Roche, and N. Lassau. 2007. Methodology for quantifying interactions between perfusion evaluated by DCE-US and hypoxia throughout tumor growth. Ultrasound Med. Biol. 33:549-560.
20. Ellis, L.M., and D.J. Hicklin. 2008. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer. 8:579-591.
21. Fletcher, E.C., and N.V. Chong. 2008. Looking beyond Lucentis on the management of macular degeneration. Eye (Lond.). 22:742-750.
22. Folkman, J. 2007. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6:273-286.
23. Fons, P., S. Chabot, J.E. Cartwright, F. Lenfant, F. L'Faqihi, J. Giustiniani, J.P. Herault, G. Gueguen, F. Bono, P. Savi, et al. 2006. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood. 108:2608-2615.
24. Gerber, H.P., and N. Ferrara. 2005. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65:671-680.
25. Giuriato, S., N. Faumont, E. Bousquet, M. Foisseau, A. Bibonne, M. Moreau, T. Al Saati, D.W. Felsher, G. Delsol, and F. Meggetto. 2007. Development of a conditional bioluminescent transplant model for TPM3-ALKinduced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy. Cancer Biol. Ther. 6:1318-1323.
26. Greenberg, J.I., D.J. Shields, S.G. Barillas, L.M. Acevedo, E. Murphy, J. Huang, L. Scheppke, C. Stockmann, R.S. Johnson, N. Angle, and D.A. Cheresh. 2008. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature. 456:809-813.
27. Habot-Wilner, Z., I.S. Barequet, Y. Ivanir, J. Moisseiev, and M. Rosner. 2010. The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization. Acta Ophthalmol. (Copenh.). 88:862-867.
28. Hamano, Y., H. Sugimoto, M.A. Soubasakos, M. Kieran, B.R. Olsen, J. Lawler, A. Sudhakar, and R. Kalluri. 2004. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 64:1570-1574.
29. Hamzah, J., M. Jugold, F. Kiessling, P. Rigby, M. Manzur, H.H. Marti, T. Rabie, S. Kaden, H.J. Gröne, G.J. Hämmerling, et al. 2008. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature. 453:410-414.
30. Hashemian, M.N., S. Moghimi, S. Kiumehr, M. Riazi, and F.A. Amoli. 2009. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats. Ophthalmic Res. 42:90-95.
31. Helfrich, I., I. Scheffrahn, S. Bartling, J. Weis, V. von Felbert, M. Middleton, M. Kato, S. Ergün, and D. Schadendorf. 2010. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J. Exp. Med. 207:491-503.
32. Heymans, O., J. Fissette, P. Vico, S. Blacher, D. Masset, and F. Brouers. 2000. Is fractal geometry useful in medicine and biomedical sciences? Med. Hypotheses. 54:360-366.
33. Hurmeric, V., T. Mumcuoglu, C. Erdurman, B. Kurt, O. Dagli, and A.H. Durukan. 2008. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Cornea. 27:357- 362.
34. Jacobs, D.S., M. Lim, K.G. Carrasquillo, and P. Rosenthal. 2009. Bevacizumab for corneal neovascularization. Ophthalmology. 116:592-593, author reply:593-594.
35. Jain, R.K. 2005. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 307:58-62.
36. Jain, R.K., L.L. Munn, and D. Fukumura. 2002. Dissecting tumour pathophysiology using intravital microscopy. Nat. Rev. Cancer. 2:266-276.
37. Koehl, G.E., A. Gaumann, and E.K. Geissler. 2009. Intravital microscopy of tumor angiogenesis and regression in the dorsal skin fold chamber: mechanistic insights and preclinical testing of therapeutic strategies. Clin. Exp. Metastasis. 26:329-344.
38. Le Bouteiller, P., A. Barakonyi, J. Giustiniani, F. Lenfant, A. Marie-Cardine, M. Aguerre-Girr, M. Rabot, I. Hilgert, F. Mami-Chouaib, J. Tabiasco, et al. 2002. Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity. Proc. Natl. Acad. Sci. USA. 99:16963-16968.
39. Liang, K.Y., and S.L. Zeger. 1986. Longitudinal data analysis using generalized linear models. Biometrika. 73:13-22.
40. Lin, M.I., and W.C. Sessa. 2004. Antiangiogenic therapy: creating a unique "window" of opportunity. Cancer Cell. 6:529-531.
41. Ma, W.W., and A.A. Adjei. 2009. Novel agents on the horizon for cancer therapy. CA Cancer J. Clin. 59:111-137.
42. Maeda, M., C. Carpenito, R.C. Russell, J. Dasanjh, L.L. Veinotte, H. Ohta, T. Yamamura, R. Tan, and F. Takei. 2005. Murine CD160, Ig-like receptor on NK cells and NKT cells, recognizes classical and nonclassical MHC class I and regulates NK cell activation. J. Immunol. 175:4426-4432.
43. Makale, M. 2007. Intravital imaging and cell invasion. Methods Enzymol. 426:375-401.
44. Man, S., G. Bocci, G. Francia, S.K. Green, S. Jothy, D. Hanahan, P. Bohlen, D.J. Hicklin, G. Bergers, and R.S. Kerbel. 2002. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 62:2731-2735.
45. Manzano, R.P., G.A. Peyman, P. Khan, P.E. Carvounis, M. Kivilcim, M. Ren, J.C. Lake, and P. Chévez-Barrios. 2007. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br. J. Ophthalmol. 91:804-807.
46. Moraczewski, A.L., R.K. Lee, P.F. Palmberg, P.J. Rosenfeld, and W.J. Feuer. 2009. Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab. Br. J. Ophthalmol. 93:589-593.
47. Oh, J.Y., M.K. Kim, M.S. Shin, H.J. Lee, J.H. Lee, and W.R. Wee. 2009. The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas. Curr. Eye Res. 34:85-91.
48. Padera, T.P., B.R. Stoll, J.B. Tooredman, D. Capen, E. di Tomaso, and R.K. Jain. 2004. Pathology: cancer cells compress intratumour vessels. Nature. 427:695.
49. Pàez-Ribes, M., E. Allen, J. Hudock, T. Takeda, H. Okuyama, F. Viñals, M. Inoue, G. Bergers, D. Hanahan, and O. Casanovas. 2009. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 15:220-231.
50. Passaniti, A., R.M. Taylor, R. Pili, Y. Guo, P.V. Long, J.A. Haney, R.R. Pauly, D.S. Grant, and G.R. Martin. 1992. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest. 67:519-528.
51. Ratner, M. 2004. Genentech discloses safety concerns over Avastin. Nat. Biotechnol. 22:1198.
52. Reichert, J.M., and V.E. Valge-Archer. 2007. Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug Discov. 6:349-356.
53. Rosenfeld, P.J., D.M. Brown, J.S. Heier, D.S. Boyer, P.K. Kaiser, C.Y. Chung, and R.Y. Kim; MARINA Study Group. 2006. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355:1419-1431.
54. Salgaller, M.L. 2003. Technology evaluation: bevacizumab, Genentech/ Roche. Curr. Opin. Mol. Ther. 5:657-667.
55. Sherris, D. 2007. Ocular drug development-future directions. Angiogenesis. 10:71-76.
56. Shojaei, F., and N. Ferrara. 2007. Antiangiogenesis to treat cancer and intraocular neovascular disorders. Lab. Invest. 87:227-230.
57. Smith, L.E., E. Wesolowski, A. McLellan, S.K. Kostyk, R. D'Amato, R. Sullivan, and P.A. D'Amore. 1994. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 35:101-111.
58. Takeda, A., J.Z. Baffi, M.E. Kleinman, W.G. Cho, M. Nozaki, K. Yamada, H. Kaneko, R.J. Albuquerque, S. Dridi, K. Saito, et al. 2009. CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature. 460:225-230.
59. Ueno, S., M.E. Pease, D.M. Wersinger, T. Masuda, S.A. Vinores, T. Licht, D.J. Zack, H. Quigley, E. Keshet, and P.A. Campochiaro. 2008. Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels. J. Cell. Physiol. 217:13-22.
60. Welch, D.R., J.E. Bisi, B.E. Miller, D. Conaway, E.A. Seftor, K.H. Yohem, L.B. Gilmore, R.E. Seftor, M. Nakajima, and M.J. Hendrix. 1991. Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. Int. J. Cancer. 47:227-237.
61. Wolfinger, R., and M. O'Connell. 1993. Generalized linear mixed models a pseudo-likelihood approach. Journal of Statistical Computation and Simulation. 48:233-243.
62. Yu, L., X. Wu, Z. Cheng, C.V. Lee, J. LeCouter, C. Campa, G. Fuh, H. Lowman, and N. Ferrara. 2008. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest. Ophthalmol. Vis. Sci. 49:522-527.
63. Zhang, Q., J. Zhang, Y. Guan, S. Zhang, C. Zhu, G.T. Xu, and L. Wang. 2009. Suppression of retinal neovascularization by the iNOS inhibitor aminoguanidine in mice of oxygen-induced retinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 247:919-927.